Halozyme Therapeutics, Inc. (HALO)

Acerca de Halozyme Therapeutics, Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Al 3 de noviembre de 2026, la acción de Halozyme Therapeutics, Inc. (HALO) subió a $130.85, un alza de 1.47% (+$1.90) frente al cierre anterior. En la sesión, las acciones han operado entre $128.25 y $131.36. Eso ubica a HALO cerca del máximo de su rango de 52 semanas, de $61.23 a $134.00. Halozyme Therapeutics, Inc. opera en el sector de biological products, (no diagnostic substances) y tiene una capitalización de mercado de aproximadamente $14.86 mil millones, con cerca de 280.7 mil acciones negociadas.

Últimas noticias de HALO

• HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?Yahoo Finance· 30 oct, 8:36 a.m. ET
• Exelixis (EXEL) vs. BMRN and NBIX: Can CABOMETYX and Pipeline Growth Revive Investor Confidence?Yahoo Finance· 29 oct, 1:18 p.m. ETEXEL
• Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings GrowthYahoo Finance· 29 oct, 9:00 a.m. ET
• What Did Halozyme Stock Investors Miss Before The Run?trefis.com· 28 oct, 5:24 a.m. ET
• Strong Royalties and New Launches Accelerate Halozyme Therapeutics’ (HALO) Growth MomentumYahoo Finance· 27 oct, 7:32 a.m. ET
• TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study DataYahoo Finance· 26 oct, 10:41 a.m. ET
• Incyte & Genmab Collaborate to Develop a New Colorectal Cancer TherapyYahoo Finance· 26 oct, 10:25 a.m. ET
• RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales FallYahoo Finance· 26 oct, 10:17 a.m. ET

Fuente: Yahoo Finance RSS · Actualizado el 3 de noviembre de 2026

¿Quieres titulares, alertas e investigación con IA de HALO en un solo lugar? Crea una cuenta gratis →

• $HALO The Hague decision will have implications for all Alteogen partnered priducts, not just Keytruda. https://www.asiae.co.kr/en/article/2026101117262634657

  @Sean29md· 2 nov, 8:09 a.m. ET

• $HALO More sold 133.90

  @WAJeff· 30 oct, 10:48 a.m. ET

• @JasonCO @Tommojg @Jblack500 @WAJeff @cynicaloptimist @BustaCapital @IsabellaDC @No_Face_character Putting on da $HALO as fugly shoe$ are in style $LLY can help with $LFST $TGTX - LFG

  @MaverikIT· 30 oct, 9:56 a.m. ET

• $HALO Important to distinguish the Munich Regional Court from the German Federal Patent Court. The latter also issued a preliminary opinion favorable to Halozyme on the validity of EP 2 797 622. The most important source is actually the October 7, 2026 judgment of the District…

  @Sean29md· 30 oct, 9:42 a.m. ET

• $HALO https://www.pinsentmasons.com/out-law/news/dutch-patent-injunction-extends-across-eight-european-countries

  @Sean29md· 30 oct, 9:20 a.m. ET

Fuente: Stocktwits. Las publicaciones de usuarios son opiniones, no hechos verificados. Ver lo que es tendencia →